DOD Biotech PCL (BKK:DOD-R) Cash-to-Debt : 4.95 (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. DOD Biotech PCL's cash to debt ratio for the quarter that ended in Mar. 2025 was 4.95.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, DOD Biotech PCL could pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for DOD Biotech PCL's Cash-to-Debt or its related term are showing as below:

BKK:DOD-R' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.64 Max: 69.18
Current: 4.95

During the past 11 years, DOD Biotech PCL's highest Cash to Debt Ratio was 69.18. The lowest was 0.08. And the median was 0.64.

BKK:DOD-R's Cash-to-Debt is ranked better than
78.98% of 1884 companies
in the Consumer Packaged Goods industry
Industry Median: 0.51 vs BKK:DOD-R: 4.95

DOD Biotech PCL Cash-to-Debt Historical Data

The historical data trend for DOD Biotech PCL's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

DOD Biotech PCL Cash-to-Debt Chart

DOD Biotech PCL Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

0.70

0.88

0.13

0.40

4.84

DOD Biotech PCL Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash-to-Debt	Get a 7-Day Free Trial															0.43	0.53	2.18	4.84	4.95

Competitive Comparison of DOD Biotech PCL's Cash-to-Debt

For the Packaged Foods subindustry, DOD Biotech PCL's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DOD Biotech PCL's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, DOD Biotech PCL's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where DOD Biotech PCL's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

DOD Biotech PCL Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

DOD Biotech PCL's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	223.088	/	(45.77	+	0.286)
	=	4.84

DOD Biotech PCL's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	223.074	/	(44.955	+	0.111)
	=	4.95

DOD Biotech PCL (BKK:DOD-R) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

DOD Biotech PCL Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

DOD Biotech PCL Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-R) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

DOD:Thailand

Address

No. 111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000

Website

https://www.dodbiotech.com

DOD Biotech PCL is principally engaged in the manufacture and distribution of food supplements and health drinks of all kinds. The company is organized into business units based on its products and services and has reportable segments as; Supplementary business, Manufacturing cosmetic business, Manufacturing extraction business, and others. A majority of its revenue is generated from the Supplementary business which manufactures and sells dietary supplements in the form of capsules, tablets, soft gels, gummies, probiotics, shot drinks, and others. Geographically, the company operates only in Thailand.

DOD Biotech PCL Headlines

No Headlines